Paul Reider - Mar 20, 2023 Form 3 Insider Report for Coherus BioSciences, Inc. (CHRS)

Role
Chief Commercial Officer
Signature
/s/ McDavid Stilwell, as Attorney-in-Fact for Paul Reider
Stock symbol
CHRS
Transactions as of
Mar 20, 2023
Transactions value $
$0
Form type
3
Date filed
3/28/2023, 06:48 PM
Next filing
Apr 4, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding CHRS Common Stock 89.5K Mar 20, 2023 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding CHRS Stock Option (Right to Buy) Mar 20, 2023 Common Stock 125K $14.76 Direct F1
holding CHRS Stock Option (Right to Buy) Mar 20, 2023 Common Stock 40K $17.06 Direct F2
holding CHRS Stock Option (Right to Buy) Mar 20, 2023 Common Stock 37.5K $15.94 Direct F3
holding CHRS Stock Option (Right to Buy) Mar 20, 2023 Common Stock 80K $9.87 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The underlying shares subject to the option vest and become exercisable as to 25% of the total number of shares subject to the option on the one year anniversary measured from March 22, 2021 and 1/48th of the total shares in successive, equal monthly installments thereafter, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.
F2 The underlying shares subject to the option vest and become exercisable as to 1/48th of the total number of shares subject to the option in successive, equal monthly installments measured from December 13, 2021, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.
F3 The underlying shares subject to the option vest and become exercisable as to 1/48th of the total number of shares subject to the option in successive, equal monthly installments measured from January 4, 2022, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.
F4 The underlying shares subject to the option vest and become exercisable as to 1/48th of the total number of shares subject to the option in successive, equal monthly installments measured from January 4, 2023, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.

Remarks:

Exhibit 24.1 - Power of Attorney